Idera Pharmaceuticals: Gains on positive data from bowel cancer drug study

Aceragen

02/06/2020 14:55

** Shares of drug developer  IDRA.O  up ~11% at $2.01
    ** Co reports prelim data from mid-stage trial testing
experimental drug, tilsotolimod, in combination with
Bristol-Myers Squibb's  BMY.N  Opdivo and Yervoy, in patients
with a type of colorectal/bowel cancer  urn:newsml:reuters.com:*:nGNX1vTkJy
    ** Combination treatment well tolerated by all 10
participants, with no discontinuations due to adverse events
    ** One patient experienced stable disease or zero disease
progression; 6 patients had reduction in size of injected
lesions
    ** Co plans to expand study and enrollment of next 10
patients to begin in Q4; data anticipated in Q2 2021
    ** Stock up ~10% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))